fbpx
All about COVID19 - An initiative from WhiteCoats that brings together updates from top curated resources exclusively for healthcare professionals

Convalescent plasma therapy aims at using antibodies from the blood of recovered COVID-19 cases, to treat those who are currently severely infected from the novel virus.   With a lot of stakes on drugs, but no results, the medical industry is turning to new technologies in need to desperately slow the current pandemic COVID-19. Recently, as a first, a 49-year-old COVID-19 ...

Cadila Pharmaceuticals is taking the lead in the race of fight against COVID-19 through its research breakthrough of immunomodulator. The company has recently tested the immunomodulator successfully in four COVID positive patients.   The development of the immunomodulator by Cadila was carried out in partnership with our country’s premier research organization – Council of Scientific and Industrial Research (CSIR). Phase -3 ...

The World Health Organisation informed that around 60 are in the pre-clinical phase world-wide. One vaccine candidate being jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology has entered phase I human clinical trials. This vaccine uses a non-replicating viral vector as the platform (similar to that used in the Ebola vaccine) to develop a vaccine with an ...

GlaxoSmithKline, a UK-based pharma giant has teamed up Chinese company Xiamen Innovax Biotech to develop a vaccine against COVID-19. The vaccine candidate COVID-19 XWG-03 is being developed by Xiamen Innovax Biotech, along with researchers from Xiamen University. The role of GlaxoSmithKline in this collaboration will be to provide access to adjuvant for use in the vaccine. Adjuvants are added to ...

While the entire world is struggling to fight against the menace of coronavirus, researchers and scientists are putting their full efforts to devise a robust test that can help early identification of the disease. Though there are existing tests based on RT-PCR, these tests require expertise and support from a healthcare professional.   Looking at the shortage of protective equipment for ...

Adar Poonawala, CEO of Serum Institute, India says COVID-19 vaccine can enter human trial by the end of 2020. The World Health Organisation (WHO) says that it will take at least 18 months for the vaccine to be ready. According to WHO, as of March 20, there are more than 40 vaccine candidates in various stages of development. The SARS-nCoV-2 ...

A cheap, safe and widely available drug that has been used to treat malaria for at least a century has emerged as the most sought-after medicine in the world for the treatment of COVID-19. Though found to be promising, should a widespread use of anti-malarial drugs be approved or should it wait until more definitive research?  The recent outbreak of ...

The rising chaotic situation across the globe due to the COVID-19 pandemic has made pharma companies to roll up their sleeves and find a potential solution as early as possible. Though there are many companies in this race of finding a potential vaccine, confirmation of human testing for the COVID-19 vaccine by September from Johnson & Johnson brings some hope ...

Altimmune based in Maryland was recently seeking collaboration with an academic institution for developing a vaccine against COVID-19. The company has presently collaborated with the University of Alabama in Birmingham for further developments.    “We need to collaborate with the academic institutions to move this program forward, and we were looking for somebody that has sort of broad experience in biology ...

The vaccine manufacturing giant Indian Immunological Limited (IIL) has joined hands with Australian University to co-develop vaccine against COVID-19. Indian Immunological is a Hyderabad based company involved in the manufacturing of vaccines for over many years and has gained a significant name in the field with their various other robust solutions. The company will be soon seen working with Griffith ...